Prostate cancer (PCa) is the second most commonly diagnosed malignancy and a leading cause of cancer death in men across the globe. Current practices for detecting PCa utilize PSA and DRE as indications for biopsy. PROGENSA PCA3^TM* is a new urine test that offers additional information to aid in the diagnosis of PCa.

PCA3 is a prostate-specific gene that is highly over expressed (60-100 times) in prostate tumors. The PROGENSA^TM PCA3 test is highly specific and uses Transcription Mediated Amplification (TMA) to quantify the PCA3 mRNA in a patient urine sample. The resulting output is a highly useful PCA3 score that can be used in conjunction with other patient history to more accurately predict biopsy outcomes.

*CE marked. Not available in the U.S.

An on-line resource for Prostate Cancer Gene 3 (PCA3) edited by healthcare professionals to provide information about advances in using genetic (PCA3) testing for improving biopsy decisions in the diagnosis of prostate cancer.
» MORE INFORMATION